Consensus on Wound Antisepsis: Update 2018

Axel Kramer a  Joachim Dissemond c  Simon Kim b  Christian Willy d  
Dieter Mayer e  Roald Papke a  Felix Tuchmann f  Ojan Assadian g

a Institute of Hygiene and Environmental Medicine and b Department of Trauma, Reconstructive Surgery and Rehabilitation Medicine, University Medicine Greifswald, Greifswald, c Department of Dermatology, Venerology and Allergology, University Hospital Essen, Essen, and d Department of Trauma Surgery, Orthopedics, Reconstructive, Plastic and Hand Surgery, Bundeswehr Hospital, Berlin, Germany; e Department of Surgery, Kantonsspital Freiburg, Freiburg, Switzerland; f Department of Dermatology and g Department of Infection Control and Hospital Epidemiology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria

Keywords
Wound antisepsis · Wounds-at-Risk Score · Antiseptics · Drug · Medical device · Octenidine · Polihexanide · Hypochlorite · Iodophors · Taurirolidine · Silver ions · Acetic acid · Negative pressure wound therapy with the instillation of antiseptics · Physical body warm atmospheric plasma · Silver sulfadiazine · Dyes · Mercury compounds · Hydrogen peroxide

Abstract
Wound antisepsis has undergone a renaissance due to the introduction of highly effective wound-compatible antimicrobial agents and the spread of multidrug-resistant organisms (MDROs). However, a strict indication must be set for the application of these agents. An infected or critically colonized wound must be treated antiseptically. In addition, systemic antibiotic therapy is required in case the infection spreads. If applied preventively, the Wounds-at-Risk Score allows an assessment of the risk for infection and thus appropriateness of the indication. The content of this updated consensus recommendation still largely consists of discussing properties of octenidine dihydrochloride (OCT), polihexanide, and iodophores. The evaluations of hypochlorite, taurirolidine, and silver ions have been updated. For critically colonized and infected chronic wounds as well as for burns, polihexanide is classified as the active agent of choice. The combination 0.1% OCT/phenoxethanol (PE) solution is suitable for acute, contaminated, and traumatic wounds, including MRSA-colonized wounds due to its deep action. For chronic wounds, preparations with 0.05% OCT are preferable. For bite, stab/puncture, and gunshot wounds, polyvinylpyrrolidone (PVP)-iodine is the first choice, while polihexanide and hypochlorite are superior to PVP-iodine for the treatment of contaminated acute and chronic wounds. For the decolonization of wounds colonized or infected with MDROs, the combination of OCT/PE is preferred. For peritoneal rinsing or rinsing of other cavities with a lack of drainage potential as well as the risk of central nervous system exposure, hypochlorite is the superior active agent. Silver-sulfadiazine is classified as dispensable, while dyes, organic mercury compounds, and hydrogen peroxide alone are classified as obsolete. As promising prospects, acetic acid, the combination of negative pressure wound therapy with the instillation of antiseptics (NPWTi), and cold atmospheric plasma are also subjects of this assessment.

© 2017 S. Karger AG, Basel
Renaissance of Xenobiotic Wound Antiseptics

Wound antiseptics lost some of their importance for more than a century due to the toxicity of Lister’s carbolic wound spray, the toxic side effects of the next generation of antiseptics such as mercury- or arsenic-based compounds, and the initial euphoria after the introduction of the antibiotic penicillin G. Reasons for the renaissance of antiseptics are the development of effective and well-tolerated antiseptic substances, the pandemic spread of multidrug resistant organisms (MDROs), a comparatively high rate of sensitization to locally applied antibiotics, the microbicidal instead of microbiostatic effect of antiseptics, the locally delimited effect with no or – in the case of polyvinylpyrrolidone-iodine (PVP-I) – few systemic consequences when correctly applied considering contraindications, and last but not least, the absence of resistance development for those antiseptic agents which damage pathogens irreversibly. For example, so far, no resistance has been observed against antiseptics with unspecific effects, such as the destruction of the bacterial cell as a whole, or the inhibition of its function with destruction of the cell membrane or blockage of negative surface charges. This is the case for octenidine dihydrochloride (OCT), polihexanide (PHMB), PVP-I, and oxidizing agents, such as hypochlorous acid, or active substances from the class of peroxides/peroxy acids, such as hydrogen peroxide ($\text{H}_2\text{O}_2$). Microbiostatic antiseptics, however, show transferable resistances, and can be partially cross-resistant with certain antibiotics. Examples are the activation of efflux pumps [1, 2] for chlorhexidine digluconate (CHD) and quaternary ammonium compounds, and a genetically coded periplasmatic Ag(I)-binding protein and 2 efflux pumps for silver ions [3]. This is also true for topically applied antibiotics such as mupirocin [4], silver sulfadiazine [5–7], neomycin, and bacitracin [8], which have all lost their significance as wound antiseptics, except for mupirocin [9], which is still used for the decolonization of MRSA (methicillin-resistant Staphylococcus aureus). Especially the over-the-counter sale (without prescription) of mupirocin as a wound antiseptic is considered to be a major cause for the increase in resistance development [5, 10], which can locally exceed more than 20% of examined hospital-associated MRSA strains [11].

The local application of antibiotics for locally confined wound infections and colonization is to be avoided, not only because of the promotion of resistance development, but also because of their microbiostatic mode of action and concentrations that are hard to adjust. Any systemic escalation of the infection, such as positive blood cultures, must be treated with systemic antibiotics in combination with topic antiseptics, if necessary.

<table>
<thead>
<tr>
<th>Microbial strain</th>
<th>Cefuroxime [269, 270]</th>
<th>OCT [50]</th>
<th>PHMB [50]</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. aureus</td>
<td>0.5 to 64</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>MRSA</td>
<td>16</td>
<td>1</td>
<td>0.5</td>
</tr>
<tr>
<td>E. faecalis</td>
<td>2 to 128</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>VRE</td>
<td>–</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>E. coli</td>
<td>8 to &gt;400</td>
<td>8</td>
<td>0.5</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>&gt;400</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>C. albicans</td>
<td>–</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Since the microbicidal effect of antibiotics can only be examined in a suspension test and has thus seldom been the focus of studies, only a few published reports on minimal inhibitory concentration (MIC) exist which could serve as a basis for comparison. Nevertheless, this literature shows that many antiseptics are vastly more effective compared to antibiotics (Table 1). For gentamicin, which is also approved for topical use as a cream, the MIC for sensitive S. aureus was 0.5–1 μg/mL, for Pseudomonas aeruginosa 2 μg/mL [12], and for Enterobacteriaceae 25–75 μg/mL [13]. In contrast, for fluoroquinolones for example, the MIC against sensitive Escherichia coli is 0.008–0.02 μg/mL, which is much lower than for OCT or PHMB, where the MIC may be up to 1,000 μg/mL for resistant strains [14]. The use of this antibiotic would not be recommendable.

The German Society for Wound Healing and Wound Treatment (Deutsche Gesellschaft für Wundheilung und Wundbehandlung) only recommends microbiological diagnostics for chronic wounds if there are signs of a systemic infectious event originating from the wound area [15]. For this reason, the local application of antibiotics used for the treatment of systemic infections should be avoided in order to circumvent the development of resistance and sensitization [16]. The WHO also does not recommend topical use of or rinsing with antibiotics in this case [17] (Table 1).

Evidence Regarding Wound Antiseptics

An infected or critically colonized wound must be microbiologically remediated in order to heal properly [18–20]. It must be determined whether the topical use of antiseptics is sufficient or if a systemic antibiotic is necessary due to septic spreading. If a wound is at risk of becoming infected, antiseptics can prevent the emergence of infection [21].
Although the proper treatment of wounds has been a challenge since the beginning of mankind, sufficient evidence is lacking for the choice of antiseptics to prevent wound infections as well as treat wounds, especially chronic ones. Many dermatological patients suffer from different types of erosive skin lesions, e.g., follicular bacterial infections [22, 23] or eczema [24]. Often, local antibiotics are used instead of considering antiseptic options for treatment, although according to expert opinion, the latter are more effective and do not pose a risk of resistance development [22]. This leads to the conclusion that further studies and observations must be undertaken to examine the potential of antiseptic treatment for these conditions. Since only a small number of clinical trials are available as the basis for decisions, all available results from studies ranging from in vitro experiments up to clinical studies, including meta-analyses, must be collected to form a plausible synopsis [18]. For this reason, all clinical studies available in PubMed were taken into account for Tables 6–9, regardless of the evidence level.

**Classification of Compounds for Wound Antisepsis**

Products declared as wound antiseptics are classified as pharmacological drugs (PDs). If the mechanical effects such as rinsing (solutions) or absorption (gauzes) are the primary mode of action and the antiseptic effect is only provided by the addition of preservatives, the product is classified as a medical device (MD). The distinction from PDs is based on the primary mode of action and the intention for use as described by the manufacturer. PDs act pharmacologically, metabolically, and/or immunologically, while MDs primarily act physically. The pharmacological mode of action can take various manifestations:

- The binding to adhesion proteins or their biochemical or immunological destruction can inhibit or prevent the attachment of bacteria [25, 26]. As long as pathogens residing and multiplying in the upper cell layers are killed, the effect is considered pharmacological, since reproduction cannot take place without adhesion on receptors and interaction with the tissue.

- Wound healing can be supported by biochemical means, such as interaction with inflammation mediators. This was observed for PVP-I [27], OCT [28], and hypochlorous acid [29].

- Healing can also be supported for aseptic wounds. This was observed for liposomal PVP-I [30] and PHMB [31, 32], although the exact mechanism has yet to be explained.

It is always considered to be a pharmacological mode of action if wound healing is supported by the antiseptic effects on cell-adherent pathogens, possibly with associated biochemical or immunological consecutive reactions. This is also true if the active substance binds to the wound tissue and offers a so-called remanent effect by gradual release [33, 34]. If the main mode of action of wound rinsing solutions or wound dressings is based on physical means, e.g., rinsing, absorption, moisture regulation, or irreversible physicochemical binding of microorganisms, they are classified as MDs. In practice, the transition between MPs and MDs is fluid, since physical and pharmacological modes of actions cannot be strictly separated. Since the classification does bear consequences for pharmacological-toxicological and clinical testing as well as user protection, the correct classification is important in terms of ethics and reimbursement. This demarcation is further complicated by the approval of some antiseptics such as PHMB as a preservative in antiseptically effective concentrations and their use in wound treatment preparations without further declaration [33, 34]. Because of this, all comparisons made within this consensus recommendation require further careful evaluation and interpretation.

**Indications**

The use of antiseptics for prophylactic or therapeutic indications in wound treatment is possible for the following objectives:

- Prevention of infection of acute wounds, e.g., after trauma, bite, or gunshot wounds
- Prevention of postsurgical wound infections (surgical site infections; SSI)
- Decolonization of wounds colonized with MDRO
- Treatment of clinically manifested wound infections, including so-called critical colonization
- Preparation for debridement or wound cleaning of chronic wounds in outpatient facilities

The interaction between microorganisms and wounds can take place on different levels (Table 2). The clinically characterized term “critical colonization” reflects the hard to define condition of the transition between physiological wound colonization and the pathological condition of a manifest local infection [35].

Although almost all wounds, especially chronic ones, are contaminated, not all patients develop an infection. Since physiological colonization is either irrelevant or – due to colonization resistance – even beneficial for the process of wound healing [36], the Wounds-at-Risk (WAR) Score [37], which is the sum of different points,
was introduced in order to evaluate the infection risk (Table 3).

If the WAR Score reaches or exceeds 3 points, an antiseptic treatment is justified.

### Criteria for Choosing Antiseptic Agents

#### Efficacy

When treating acute wounds, a microbicidal effect and broad spectrum of activity are desirable. Only in certain cases does the substance have to be virucidal and additionally effective against bacterial spores. For chronic wounds, the spectrum of activity must only encompass Gram-positive and Gram-negative bacteria if no special circumstances have been diagnosed. There should be no risk for the development of resistance, especially cross-resistance towards antibiotics.

The efficacy of antiseptics is expected to result in killing of test organisms $\geq 3 \log_{10}$ [38, 39] for a typical type of organic load within the declared exposure time.

In some cases, the efficacy is additionally tested without an organic load typical for wounds, although this does not correspond to the application situation, unless the load is significantly reduced, for example by repeated rinsing. Without an organic load, the efficacy is expected to be $\geq 5 \log_{10}$ versus bacteria and $\geq 4 \log_{10}$ versus *Candida albicans* [38].

#### Tolerability

The tolerability of antiseptics in wounds is supposed to be equal to Ringer solution, physiological saline, or an inert hydrogel. Ideally, wound healing is promoted.

A good point of orientation would be to follow the practical approach of not applying anything to chronic wounds which should not be applied to the eyes. This is true for PVP-I up to 5% and for PHMB up to 0.02% [40–42], but not for silver sulfadiazine, CHD, or OCT (0.1%). If adjacent tissues can be exposed in the wound treatment, such as cartilage, central nervous system (CNS), or peritoneum, the compatibility must be clarified. Furthermore, sensitization potential including anaphylaxis risk should be low or absent; there should also be no risk of long-term adverse effects such as mutagenicity, carcinogenicity, or teratogenicity. If the quotient of bactericidal efficacy and tolerability against mouse fibroblasts in vitro, both tested under the same conditions, is $>1$, the tolerance for the antiseptic of eukaryotic cells is better than that of bacteria. This is true for OCT, PHMB, and almost for PVP-I (Table 4). A detailed observation about the selective antiseptic effect can be made when, in cocultures of human cells and bacteria, the prokaryotic cells are destroyed, while the eukaryotic cells survive, or bacteria in a comparable solution are killed without damage to human cells. This is demonstrated for sodium hypochlorite (NaOCl) [43], PHMB [44], and PVP-I [45]. Analogously, the treatment of epidermis equivalents...

<table>
<thead>
<tr>
<th>Term</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contamination</td>
<td>Microorganisms are present and have attached to the tissue (microbial attachment) without (initial) proliferation</td>
</tr>
<tr>
<td>Colonization</td>
<td>Microorganisms are present and are proliferating; a clinically significant immunological host reaction is (initially) absent</td>
</tr>
<tr>
<td>Critical colonization</td>
<td>Microbial proliferation without the formation of classical signs of infection but delayed wound healing due to toxin production/or the wound is colonized with antibiotic resistant strains without signs and symptoms of infection</td>
</tr>
<tr>
<td>Local infection</td>
<td>Clinically observable, immunological host reaction with the typical signs of infection including redness (erythema 1–2 cm measured from the wound margin) with tendencies of increase could be equivalent to spreading infection with the risk of generalization, swelling, increased local skin/tissue temperature, pain, functional impairment, and increase in exudate quantity and viscosity, for example, perceptible odor and stagnation in wound healing</td>
</tr>
<tr>
<td>Systemic infection</td>
<td>In addition to the local inflammatory reactions, signs of a systemic host reaction such as leukocytosis, increase in C-reactive protein and fever</td>
</tr>
</tbody>
</table>

### Table 2. Classification of the microbial status of wounds

<table>
<thead>
<tr>
<th>Term</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contamination</td>
<td>Microorganisms are present and have attached to the tissue (microbial attachment) without (initial) proliferation</td>
</tr>
<tr>
<td>Colonization</td>
<td>Microorganisms are present and are proliferating; a clinically significant immunological host reaction is (initially) absent</td>
</tr>
<tr>
<td>Critical colonization</td>
<td>Microbial proliferation without the formation of classical signs of infection but delayed wound healing due to toxin production/or the wound is colonized with antibiotic resistant strains without signs and symptoms of infection</td>
</tr>
<tr>
<td>Local infection</td>
<td>Clinically observable, immunological host reaction with the typical signs of infection including redness (erythema 1–2 cm measured from the wound margin) with tendencies of increase could be equivalent to spreading infection with the risk of generalization, swelling, increased local skin/tissue temperature, pain, functional impairment, and increase in exudate quantity and viscosity, for example, perceptible odor and stagnation in wound healing</td>
</tr>
<tr>
<td>Systemic infection</td>
<td>In addition to the local inflammatory reactions, signs of a systemic host reaction such as leukocytosis, increase in C-reactive protein and fever</td>
</tr>
</tbody>
</table>
derived from human keratinocytes with OCT alone or in combination with test organisms demonstrated no cytotoxic effect in viable keratinocytes [51]. In contrast, H$_2$O$_2$ inhibits mammalian cells beginning with a concentration of 8.5 mg/L [46], thus inhibiting fibroblasts, whereas bacteria still survive [47]. However, this is not transferable to the endogenous formation of H$_2$O$_2$ occurring in the context of the nonspecific immune response, for example by granulocytes. Thus, 0.003% H$_2$O$_2$ already inhibits the cytolytic activity of natural killer cells, but the killer cells remain vital [48]. Even if, for example, H$_2$O$_2$ is formed in noncytotoxic concentrations in medical honey by glucose oxidase, this is not comparable with the external antiseptic application of pure H$_2$O$_2$ alone [49].

In acute wounds the fast-acting effect of the antiseptic is at the forefront, under certain circumstances with a necessary depth effect, for example in patients with bite, puncture, or gunshot injuries. For chronic wounds, a longer exposure time is acceptable for reaching the antiseptic effect due to repeated application and/or remaining on the wound. Wound healing should also be promoted here.

<table>
<thead>
<tr>
<th>Risk class</th>
<th>Risk condition (based on risk status and different indications)</th>
<th>Point score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Acquired immunosuppressive disease (e.g., diabetes mellitus)</td>
<td>Per risk 1 point</td>
</tr>
<tr>
<td></td>
<td>Acquired immune defect due to medical therapy such as cyclosporine, methotrexate, glucocorticoids, or antibodies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solid tumor disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Systemic hematological disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Postsurgical wound healing disorder, which results in (unplanned) secondary healing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Potentially heavily contaminated wounds (e.g., perineum, genitals)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Problematic hygienic conditions related to social or occupational environment (e.g., agriculture, lorry driver)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patient age &gt;80 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Young age of patient (premature infants, babies, infants)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wounds persisting for &gt;1 year</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wound dimensions of &gt;10 cm$^2$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic wounds of any etiology having a depth of &gt;1.5 cm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extended inpatient status &gt;3 weeks</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Severe acquired immune defects (e.g., HIV infection)</td>
<td>Per risk 2 points</td>
</tr>
<tr>
<td></td>
<td>Heavily contaminated acute wounds</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bite, stab, and gunshot wounds penetrating 1.5–3.5 cm</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Severe innate immunodeficiency such as Wiskott-Aldrich, Di-George syndrome, immunodeficiency after stem cell transplantation, AIDS, immunosuppressive therapy [271]</td>
<td>Per risk 3 points</td>
</tr>
<tr>
<td></td>
<td>Burn wounds with involvement of &gt;15% BSA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Traumatically contaminated wound after debridement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wounds that have a direct connection to organs or functional structures (e.g., including joints) or which contain foreign material</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bite, stab, and gunshot wounds penetrating &gt;3.5 cm</td>
<td></td>
</tr>
</tbody>
</table>

Taking into account the different properties of antiseptic active ingredients (Table 5), the following development trends are apparent. PVP-I has partly lost importance due to the introduction of more recent and advanced substances. By solving the stability problem, the combination of sodium hypochlorite/hypochlorous acid...
(HOCl/OCl\(^-\)) or sodium hypochlorite (NaOCl) is available as an additional option. Acetic acid (AA) or combinations with fruit acids such as lactic, malic, citric, fumaric, or oxalic acid are gaining increasing interest, in particular due to their efficacy against \textit{P. aeruginosa} and the promotion of wound healing, but also due to their availability in countries with limited resources.

### Properties of Selected Antiseptic Active Agents

Iodophores and modern compounds such as OCT, PHMB, and stabilized hypochlorite meet the requirements for antiseptic activity in vitro. Remnant effects are displayed only by OCT, PHMB, and CHD. Wound healing is enhanced by PHMB, hypochlorite, and AA depending on the concentration. For PVP-I there is an increased risk of sensitization as well as absorptive side effects, particularly in thyroid disorders.

#### OCTenidine

**In vitro and Animal Experiments**

OCT shows superior efficacy [50] in the quantitative suspension test without protein load compared with PVP-I, PHMB, and CHD [51]. In relation to cytotoxicity, OCT is superior to PVP-I [52, 53]. When tested on metal carriers under load (artificial wound fluid), PVP-I solution was effective within a time frame of 5 min, whereas gels based on OCT (0.05%) or PHMB (0.04 or 0.02%) needed 30 min or 3 h (PHMB 0.02%) to take effect [39]. PVP-I was also most effective in an in vitro wound model with \textit{S. aureus}, followed by OCT and PHMB [54]. However, OCT showed superior efficacy in a biofilm model with \textit{P. aeruginosa} PVP-I [55]. The \textit{S. aureus} biofilm was almost completely eliminated within 5 min [56]. Even in experimental burns in rats, OCT significantly exceeded both PHMB and PVP-I tested against \textit{P. aeruginosa} [57]. CHD interacts antagonistically with gentamicin and synergistically with OCT [58]. In vitro, phagocytosis and growth factors, such as the platelet-derived growth factor, are stimulated by OCT [59], which can be beneficial for wound healing.

#### Side Effects

When OCT/phenoxyethanol (PE) was used in the epicutaneous patch test, a negative response was found for OCT, while a positive response to PE and cocamidopropyl betaine was detectable. However, the distinction between allergic and irritating reactions was inconclusive.

### Table 5. Properties of wound antiseptics relevant for antimicrobial agents used on wounds

<table>
<thead>
<tr>
<th>Compound</th>
<th>Antimicrobial onset time</th>
<th>Deep effect(^b)</th>
<th>Development of resistance</th>
<th>Wound healing</th>
<th>Cartilage tolerability</th>
<th>Sensibilization</th>
<th>Systemic risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ag(^+)</td>
<td>≥24 h(^a) [272]</td>
<td>3</td>
<td>Yes</td>
<td>Inhibition [191, 192]</td>
<td>?</td>
<td>No</td>
<td>Yes [273]</td>
</tr>
<tr>
<td>CHD</td>
<td>3–10 h(^a) [43]</td>
<td>1</td>
<td></td>
<td>No inhibition [274]</td>
<td>No</td>
<td>Yes (rare), anaphylaxis ((n &gt; 200))</td>
<td>?(^e)</td>
</tr>
<tr>
<td>AA</td>
<td>15–30 s [49]</td>
<td>2</td>
<td>No</td>
<td>At 0.15% supportive [229, 275, 276]</td>
<td>?</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>OCl(^-)</td>
<td>30 s to 5 min(^e) [277]</td>
<td>2</td>
<td></td>
<td>Supportive [278]</td>
<td>?</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>OCT</td>
<td>3–10 h(^a) [39]</td>
<td>1(^d)</td>
<td>No inhibition [30, 36]</td>
<td>No [279]</td>
<td>No</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHMB</td>
<td>3–10 h(^a) [39]</td>
<td>2</td>
<td>Supportive [94]</td>
<td>≤0.005% [279]</td>
<td>Yes (rare), anaphylaxis ((n = 3))</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PVP-I</td>
<td>30 min(^a) [39]</td>
<td>3</td>
<td>Partial inhibition [172]</td>
<td>Yes [279]</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>

1, superficial effect due to high protein binding; 2, shallow penetration depth; 3, larger than 2.

\(^a\) Test-carrier (Tc) with organic load [39, 272]. \(^b\) Due to a lack of experimental data, theoretical extrapolation based on physicochemical properties or demonstrated absorption. \(^c\) Without load. \(^d\) In combination with phenoxyethanol 2 or 3. \(^e\) Possibility of separation of 4-chloraniline from the chlorhexidine molecule [76].

Consensus on Wound Antisepsis: Update 2018

Skin Pharmacol Physiol 2018;31:28–58
DOI: 10.1159/000481545
On the basis of the low absorption determined only after removal of the upper skin barrier, no systemic absorption is to be expected when applied to wounds [60].

**Clinical Studies**

OCT is available as a solution and a gel. The antiseptic (OCT/PE) itself as well as the rinse and the gel are well tolerated, as shown by studies (Table 6) and case reports [62–64]. As an MD (rinse), it is suitable for wound cleansing [62] and supports biofilm removal [59]. Especially the gel is particularly suitable for antisepsis in patients with burn injuries. OCT is superior to silver and PVP-I in the latter case (Table 6). In the surgical treatment of traumatic amputation and splinter injuries which were colonized with MDRO, an antibiotic treatment was not necessary after se-rological and microbiological exclusion of a florid systemic infection by antiseptic wound care with OCT/PE in conjunction with negative pressure wound therapy (NPWT) [65, 66]. With the introduction of a new treatment algorithm for chronic lower leg and foot ulcers in a surgical setting, the efficacy of OCT/PE was confirmed in a double-blind, randomized controlled trial [67].

<table>
<thead>
<tr>
<th>Type of wound</th>
<th>Comparison</th>
<th>Result</th>
<th>Study design</th>
<th>Sample size, n</th>
<th>Year</th>
<th>Study design</th>
</tr>
</thead>
<tbody>
<tr>
<td>VLU</td>
<td>W vs. W with OCT vs. OCT wound gel, no difference in infection rate at beginning</td>
<td>Wound healing and time to heal was significantly better in both OCT study arms, lowest costs in wound-gel study section</td>
<td>Prospective open-label cohort study</td>
<td>17/17/15</td>
<td>2016</td>
<td>[280]</td>
</tr>
<tr>
<td>VLU</td>
<td>W with OCT vs. W with silver</td>
<td>OCT showed significantly rapid healing and reduction of pain, microbial eradication after 28 and 50 days</td>
<td>RCT</td>
<td>40/40</td>
<td>2015</td>
<td>[281]</td>
</tr>
<tr>
<td>Neoplastic ulcer</td>
<td>OCT-soaked W; comparison baseline vs. after 3 weeks of treatment</td>
<td>Significantly faster wound healing, significant eradication of potentially pathogenic Gram-positive and Gram-negative bacteria, no adverse events</td>
<td>Prospective observational study</td>
<td>30</td>
<td>2013</td>
<td>[282]</td>
</tr>
<tr>
<td>Split-skin harvest sites</td>
<td>OCT-hydrogel vs. hydrogel</td>
<td>Significant reduction of wound colonization, no difference in time to heal</td>
<td>Double-blind RCT</td>
<td>31/30</td>
<td>2012</td>
<td>[36]</td>
</tr>
<tr>
<td>VLU</td>
<td>OCT/PE vs. Ringer lactate solution</td>
<td>No difference in time to heal; for OCT fewer adverse events</td>
<td>Double-blind RCT</td>
<td>60/66</td>
<td>2012</td>
<td>[283]</td>
</tr>
<tr>
<td>Second-degree burn</td>
<td>Irrigation of wound with OCT/PE, thereafter OCT gel vs. silver sulfadiazine</td>
<td>Significant reduction of pain in OCT study arm, tendentially improved wound healing; possibly no difference observable due to initial OCT treatment in both study sections</td>
<td>Prospective RCT, contralateral site served as control</td>
<td>30/30</td>
<td>2011</td>
<td>[284]</td>
</tr>
<tr>
<td>Musculoskeletal infection</td>
<td>OCT irrigation and drainage + OCT-soaked gauze</td>
<td>After 5–24 days eradication of all pathogens, no adverse events</td>
<td>Prospective observational study</td>
<td>8</td>
<td>2010</td>
<td>[285]</td>
</tr>
<tr>
<td>Neoplastic ulcer</td>
<td>OCT/PE-soaked gauze; comparison of baseline vs. after 3 weeks of treatment</td>
<td>Eradication of <em>S. epidermidis</em> and <em>P. aeruginosa</em>, reduction of necrosis, exudate, erythema, and edema: 1× persistence of <em>P. aeruginosa</em>, 1× persistence of <em>E. coli</em>, and 2× persistence of <em>E. faecalis</em></td>
<td>Prospective observational study</td>
<td>16</td>
<td>2008</td>
<td>[286]</td>
</tr>
</tbody>
</table>

[60]. On the basis of the low absorption determined only after removal of the upper skin barrier, no systemic absorption is to be expected when applied to wounds [61].
outpatient clinic, OCT-based antiseptics were implement-
ed instead of obsolete agents such as CHD, ethacridine, H$_2$O$_2$, silver sulfadiazine, or local antibiotics, with an almost 3-fold reduction in the total cost [67]. OCT was also effective in patients with inflammatory acne vulgaris [68].

_Caveats_

During the past few years, several misapplications of OCT/PE have been recorded. In these cases, the compound was applied in puncture wounds, bite wounds, or abscess cavities by syringe with pressure into the wound channel and deep tissue, instead of only superficial application. The subsequent edematous swellings with tissue damage required partial surgical revision [69]. Only superficial application by means of swabs or spray is recommended [70]. Any unwanted tissue reactions are improbable in this case, because no local pressure necrosis was observed upon flushing locally limited skin soft-tissue infections in the hand area ($n = 10$) with applied drainage [71]. Since OCT is practically not reabsorbed, any insertion into the skin or insertion canals is to be avoided. According to the manufacturer, the use of OCT/PE for wound treatment without medical supervision should not be extended for more than 2 weeks, as the only data available are from a continuous application period of up to approximately 14 days.

_Contraindications_

Peritoneal lavage, retroperitoneal and intravenous application, allergy, application to hyaline cartilage, and CNS structures are contraindications. Interaction with CNS structures is recorded for CHD, and is considered valid for OCT as well until further data are available [59].

**Polihexanide**

In 1979, Good [72] combined PHMB, which until then had only been used as disinfectant, with polyethylene glycol 4000 to achieve improved wetting for use on wounds [72, 73]. In the 1980s, PHMB was introduced by Willenegger in Switzerland [74]. PHMB can be seen as a virtually detoxified CHD, as the molecular structure of PHMB monomers closely resembles the structure of CHD molecules, except for the terminal NH-group of CHD consisting of 4-chloroaniline, which is a potential human carcinogen [75]. This similarity explains both the comparable antiseptic efficacy and the worse tolerability of CHD compared to PHMB, due to the release of 4-chloroaniline in vivo [76]. Depending on the manufacturer, wound irrigation solutions release 0.02, 0.04, or 0.1% PHMB, wound gel 0.1%, and wound dressings 0.1%. Reduction by ≥3 log$_{10}$ of typical wound contamination on test specimens was achieved by wound gel with a concentra-
tion of 0.1% in 30 min, 0.04% in 3 h, and 0.02% in 10 h. Enterococcus faecium was not sufficiently elimin-
ed in 24 h [39]. As different concentrations of PHMB solutions were not examined on test specimens, it is not possible to deduce the optimal concentration for wound treatment. A single irrigation of contaminated traumatic wounds for 3 min was shown to be effective in a clinical trial on the prevention of SSI [21], and treatment dura-
tion should not fall below this as long as there are no other results. Using wound gel, exposure for at least 3 h is needed [39].

**Results from in vitro and Animal Tests**

The efficacy of PHMB does not substantially differ from that of OCT. PHMB is equally effective against methicillin-sensitive _S. aureus_ and MRSA [77]. Higher pH levels, which typically develop in wounds (6.5–8.5) [78], decrease the efficacy of PVP-I but significantly im-
prove that of PHMB. This suggests that PHMB might be advantageous for the management of wound infections, as both _S. aureus_ and _P. aeruginosa_ exhibited increased susceptibility to the antiseptic with rising pH levels. The inhibitory activity of chlorhexidine and OCT was only marginally affected by the pH in vitro, although a statisti-
cally significant improvement was observed against _S. a-
ureus_ at pH 9 for OCT [79].

In combination with undecylenamidopropyl betaine (Betaine), the antimicrobial effect is enhanced because of altered physical properties [80, 81], while in vitro cy-
totoxicity is reduced [80] and cleaning performance is improved [82]; the latter one could not be confirmed in a newer study because of the interference of the surfac-
tant with the protein measurement [322]. Intracellular elimination is remarkable, as shown for _E. coli_ [83], MRSA [84], and _Acanthamoeba_ species [85]. Thus, PHMB (0.02%) is the preferred agent for the treatment of _Acanthamoeba_ keratitis [85]. Efficacy against _P. aeruginosa_ can still be observed in the presence of 4% al-
bumin [86], 4.5% blood + 4.5% albumin [87], and wound exudates, while the expression of elastase is in-
ihibited at the same time [88]. In a wound model on pigs, MRSA was significantly reduced after 72 h by PHMB in a wound treatment matrix based on collagen, while silver dressings were ineffective [89]. PHMB was effective against biofilm in vitro [90] and in animal models [91]. Loaded onto nanocellulose, PHMB was antimicrobi-
ally more effective than PVP-I [92]. No antagonism could

---

Consensus on Wound Antisepsis: Update 2018

Skin Pharmacol Physiol 2018;31:28–58

DOI: 10.1159/000481545
be shown against oxacillin, penicillin G, ampicillin, cefazolin, cefuroxime, imipenem, gentamicin, erythromycin, doxycycline, levofloxacin, linezolid, or vancomycin [93]. Both in cell culture and animal wound models (rat, pig), wound healing was improved [31, 94–96]. Results of in vitro and animal tests (rat) are promising for the combination of PHMB and sericine, an ameliorator of wound healing, in a dressing [97]. Capillary density was significantly increased in the cremaster muscle (rat) by exposure to PHMB and OCT, while the diameter of arterioles was significantly increased only by PHMB [98]. The irritation potency of 0.02% PHMB is lower than that of antibiotic eye drops [99].

In 2011, the Committee for Risk Assessment of the European Chemicals Agency (ECHA) raised the suspicion that PHMB was a category-2 carcinogen (Carc. 2). Consequently, all products containing PHMB in a concentration of at least 1% had to be labeled accordingly from January 1, 2015. Compositions containing 0.1% required an annotation on the safety data sheet. This classification by the ECHA as category 2 “suspected of causing cancer” lacks scientific proof. The 2 studies used for the evaluation were feeding studies using extremely high PHMB concentrations far in excess of the no-observed-adverse-effect level. Only in the highest tested concentration of 4,000 ppm did the frequency of cases with hemangiosarcoma significantly increase, but at ≤1,200 ppm this was not the case. Neither genotoxicity nor epigenetic changes [100] could be shown; therefore, it is very likely that hemangiosarcoma was triggered by enforced proliferation of the endothelium, as was proven for PHMB in wound healing. For risk assessment, it is critical that there be no systemic absorption up to the detection threshold of 10 μg for PHMB, so a health hazard can be excluded for antiseptic use according to regulations [detailed statement with references in 101, 102].

It is important to note that, in this context, the ECHA specifically excluded PHMB from the labeling requirements when used invasively or on the skin surface for wound irrigation or with dressings. The reason for this exemption is the regulatory classification of hazardous substances and their preparation to ensure occupational and environmental safety. Particularly exposure to larger amounts, which is possible during the production of these substances, has to be considered. Personnel should be appropriately protected against critical exposure.

Undesirable Effects

Two cases of a possible anaphylactic reaction triggered by PHMB could not be verified in the skin-prick test [103]. One patient with a grade III anaphylactic reaction had IgE against both PHMB and CHD. Due to the similar structures, it is discussed that sensitization was caused by a prior treatment with CHD, so a known allergy against CHD might be linked to a risk for PHMB anaphylaxis [104]. In the second case, only IgE against PHMB was proven [105]. A further suspected case of anaphylaxis was reported after wound application [106]. Contact allergies are rare, with a frequency of ≤0.08% in regard to the frequent use of PHMB, especially as a preservative [107]. This suggests that antiseptic substances should be limited to medical applications.

Clinical Trials

PHMB is available as a solution, hydrogel, and in wound dressings [108]. It is well tolerated [109], antiseptically effective against MRSA and VRE (vancomycin-resistant Enterococcus) [110–112], can be used for wound irrigation, is suitable as an antiseptic for critically colonized and infected chronic wounds, including burns [37, 94, 113–124], and, in combination with NPWT, can be used for instillation (NPWTi). It is superior to Ag+ and PVP-I regarding wound healing [123] (Table 7). Upon application of wound dressings impregnated with 0.2% PHMB, epidermally applied Staphylococcus epidermidis were completely eliminated in 24 h [125]. The same was shown for P. aeruginosa in an animal model [126]. Application for pre- and postoperative wound treatment significantly reduced the rate of SSI (Table 7). Cytotoxically, wound dressings do not differ from PHMB-free dressings [127]. After a 4-week unsuccessful treatment of a diabetic foot ulcer with PHMB/betaine gel, the healing process commenced after a 4-week treatment with OCT gel [128]. In cases with human papillomavirus infection, the viral elimination was significantly improved by local treatment with PHMB, examined after 3 and 6 months, which could open a new area of application [129].

Caveats

Due to the relatively strong binding onto tissue structures, the same restrictions as those for OCT should apply, although no clinical reports are available yet. This is supported by the appearance of grayish, inert tissue after retroperitoneal, mediastinal, and partially inguinal application for more than 5–10 days. This tissue had to be removed in order to permit the formation of granulation.
### Table 7. Summary of clinical study findings for PHMB

<table>
<thead>
<tr>
<th>Type of wound</th>
<th>Comparison</th>
<th>Result</th>
<th>Study design</th>
<th>Sample size, n</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Traumatic soft tissue injuries</td>
<td>0.04% PHMB, 1% PVP-I, 4% WPO, Ringer solution</td>
<td>SSI rate: 1.9/4.8/11.7/5.9; PHMB was more effective in preventing infection in deep incisional wounds (A1 and A2 SSI), in contusion wounds only in A2 SSI</td>
<td>Longitudinal cohort study</td>
<td>3,264/2,552/643/645</td>
<td>2017 [21]</td>
</tr>
<tr>
<td>Pressure and VLU</td>
<td>PHMB/betaine solution vs. NaCl solution</td>
<td>Significant improvement of inflammation and wound healing, no difference in pain scores</td>
<td>Single-blinded RCT</td>
<td>143/146</td>
<td>2016 [287]</td>
</tr>
<tr>
<td>Wounds in elderly patients</td>
<td>PHMB/betaine solution</td>
<td>Significant decolonization with 32% success ($p &lt; 0.05$)</td>
<td>Prospective controlled nonrandomized open-label study</td>
<td>200/99</td>
<td>2016 [112]</td>
</tr>
<tr>
<td>Nonhealing wounds after cardiothoracic surgery</td>
<td>PHMB 0.5% vs. moist gauze soaked with Ringer solution</td>
<td>Superficial infection 38 vs. 47%, (ns), deep infection 44 vs. 40% (ns), wound healing after 15±5 vs. 16±3 days (ns); wound healing in 67 vs. 44% (ns); PHMB: patients without complete wound healing showed better epithelialization, after 12 h CRP was significantly lower than controls</td>
<td>Prospective open randomized cohort study</td>
<td>15/16</td>
<td>2015 [288]</td>
</tr>
<tr>
<td>Chronic wounds</td>
<td>PHMB gel vs. betaine gel</td>
<td>Significant reduction in wound size, pain, fibrin slough, and necrosis; reduction of exudate</td>
<td>Multicenter observational study</td>
<td>120</td>
<td>2014 [289]</td>
</tr>
<tr>
<td>Grade II burns</td>
<td>PHMB gel vs. betaine gel</td>
<td>Less pain medication, good progress in wound healing with formation of granulation tissue and epithelialization; reduction of erythema after 2 days; no infection during mean treatment of 11.2 days</td>
<td>Observational study</td>
<td>20</td>
<td>2014 [290]</td>
</tr>
<tr>
<td>Postsurgical subcutaneous abdominal infections</td>
<td>NPWTi with 0.04% PHMB-soaked gauze vs. NPWT</td>
<td>Reduced duration of treatment</td>
<td>Prospective case-control study</td>
<td>16</td>
<td>2014 [291]</td>
</tr>
<tr>
<td>Wounds after cardiothoracic surgery</td>
<td>W vs. W+PHBM</td>
<td>PHMB: significant decrease of SSI</td>
<td>Cohort study</td>
<td>692/707</td>
<td>2013 [292]</td>
</tr>
<tr>
<td>Critically colonized and infected chronic wounds</td>
<td>PHMB vs. Ag-W</td>
<td>PHMB: significantly faster pain reduction and elimination of microorganisms</td>
<td>RCT</td>
<td>21/18</td>
<td>2012 [293]</td>
</tr>
<tr>
<td>Entry point of external fixator</td>
<td>W vs. W+PHBM</td>
<td>PHMB: significant decrease of SSI</td>
<td>RCT</td>
<td>18/22</td>
<td>2012 [294]</td>
</tr>
<tr>
<td>Lower-limb and foot ulcers</td>
<td>W vs. W+PHBM</td>
<td>PHMB: significantly faster pain reduction and elimination of microorganisms, tendentially faster wound healing</td>
<td>Double-blinded RCT</td>
<td>22/23</td>
<td>2011 [295]</td>
</tr>
<tr>
<td>Burns</td>
<td>W vs. W+PHBM</td>
<td>PHMB: significant pain reduction and fewer dressing changes</td>
<td>RCT</td>
<td>30/30</td>
<td>2011 [296]</td>
</tr>
</tbody>
</table>
tissue, even after infection control independent of PHMB use as a single substance or in combination with betaine (Fig. 1a, b).

**Contraindications**

The 2 most important contraindications are possible allergy and application during the first 4 months of pregnancy. In later stages its use should follow strict observance of a benefit-risk assessment.

**Sodium Hypochlorite/Hypochlorous Acid**

The successful stabilization of the combination NaOCl/HOCl provided an ecologically relevant new development, because aqueous sodium chloride solution is electrochemically converted for its production. The activated solution is also called electrolyzed water [130]. The currently used concentration amounts are 0.004% each for NaOCl and HOCl, and <0.06% for NaOCl as a monosubstance. In contrast to surface-active substances, the ion OCl− is formed during phagocytosis through enzyme mediation by myeloperoxidase, eosinophilic peroxidase, and superoxide dismutase, and presents a physiological bactericidal mechanism [131].

**Results from in vitro and Animal Tests**

In tests without wound-related contamination, e.g., proteins or blood, and more specifically only in aqueous solution, NaOCl/HOCl and NaOCl are highly effective against vegetative bacteria, bacterial spores, aspergilli, oocysts of cryptosporidia, and coated viruses (HIV, HBV).

<table>
<thead>
<tr>
<th>Type of wound</th>
<th>Comparison</th>
<th>Result</th>
<th>Study design</th>
<th>Sample size, n</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Split-skin harvest sites</td>
<td>CHD W vs. PHMB W</td>
<td>PHMB: significantly faster reepithelialization and lower pain score</td>
<td>RCT</td>
<td>21/21</td>
<td>2011 [297]</td>
</tr>
<tr>
<td>Infected orthopedic implants</td>
<td>NPWTi with PHMB 0.04%</td>
<td>86% of patients with acute and 80% of patients with late-onset infections kept their implant during a follow-up time of 4–6 months</td>
<td>Prospective multicenter observational study</td>
<td>32</td>
<td>2011 [298]</td>
</tr>
<tr>
<td>VLU</td>
<td>NaCl vs. PHMB solution</td>
<td>PHMB: significantly faster bacterial elimination</td>
<td>Prospective cohort study</td>
<td>20/20</td>
<td>2010 [299]</td>
</tr>
<tr>
<td>Postsurgical wounds</td>
<td>W vs. W+PHMB 0.2% (first and possibly second dressing after surgical procedure)</td>
<td>PHMB: significant reduction in SSI, particularly of MRSA infection</td>
<td>Historic comparison</td>
<td>9,372/10,202</td>
<td>2008 [300]</td>
</tr>
<tr>
<td>Chronic wounds</td>
<td>NaCl vs. 0.1% PHMB gel</td>
<td>PHMB: after 2 weeks significantly faster bacterial elimination, faster wound healing, less pain, less exudate, improved granulation</td>
<td>Randomized nonblinded cohort study</td>
<td>64/78</td>
<td>2008 [301]</td>
</tr>
<tr>
<td>Burns</td>
<td>PVP-I, 1% silver nitrate, 0.04% PHMB</td>
<td>PHMB: improved epithelialization and elimination of malodor; deep necrosis and slough observed in PVP-I and silver nitrate study section</td>
<td>Parallel intervention on contralateral symmetric wounds</td>
<td>4</td>
<td>2007 [113]</td>
</tr>
<tr>
<td>Acute contaminated wounds</td>
<td>PHMB-wetted gauze (0.04%) vs. Ringer solution</td>
<td>Significant faster bacterial elimination, reduction of inflammation</td>
<td>Double-blinded RCT</td>
<td>28/22</td>
<td>2006 [302]</td>
</tr>
<tr>
<td>Infected wounds</td>
<td>W vs. W+PHBM</td>
<td>PHMB: improved control of wound colonization</td>
<td>RCT</td>
<td>21/21</td>
<td>2004 [303]</td>
</tr>
</tbody>
</table>

NPWTi, negative pressure wound therapy with instillation of antiseptics; W, wound dressing.
The combination of PHMB/betaine was slightly less effective than NaOCl/HOCl against biofilm [132]. The speed of effect was superior to PVP-I, OCT, and PHMB [130, 133–137]. It can be assumed that the efficacy is reduced by protein or blood contamination, which can be reversed by repetitive extensive wound irrigation. The survival rate of rats with experimental peritonitis was significantly increased compared to a treatment with NaCl without undesirable effects [138]. By stabilization of the cell membrane, the release of cytokines from mast cells is inhibited without intracellular impairment, possibly contributing to an anti-inflammatory effect [29]. NaOCl/HOCl was not or barely irritating on chick chorioallantoic membranes [323]. Furthermore, no evidence for cytotoxicity could be found in a 3D model of the skin [132]. There is no evidence for toxic risks [139]. The feeding of laboratory animals with 5 ppm is a safe alternative instead of sterile water [140]. There is no evidence that NaOCl poses a carcinogenic hazard [141, 142].
Undesirable Effects

Rinsing of the mediastinum in heart surgery with NaOCl/HOCl prior to wound closure was significantly associated with perioperative alterations of the ECG, including ST elevation, but without hemodynamic disturbances [143].

Clinical Trials

Case studies on NaOCl/HOCl report decolonization of MRSA infections on skin and the base of the skull [144, 145], decolonization of MRSA, P. aeruginosa, and E. coli in chronic diabetic ulcers [146], and successful adjuvant application in the treatment of necrotizing soft tissue infection [147], osteitis [145], and osteomyelitis [148]. In cases of peritonitis, partially with peritoneal abscesses (n = 7), no bacterial growth was detectable 3–7 days after irrigating twice daily for 9–12 days [149]. Postoperative complications including SSI were significantly reduced in patients with peritonitis without symptoms of intolerance [150]. The irrigation of infected chronic wounds was well tolerated [151], also in combination with NPWT [152]. The combination NaOCl/HOCl with a hydrophilically coated wound dressing, to which microorganisms adhere and bind irreversibly, appears promising and to lack the subsequent physiological immune response impairment that is triggered by OCl⁻ (Table 8).

Iodophore

The introduction of iodophores, complexes of iodine and macromolecules, in 1956 sparked a renaissance of antisepsis. However, demands for stricter indications were already made in 1984, with a call for each specialty to more rigorously watch for undesired effects to prefer an antiseptic agent with similar antimicrobial spectrum but fewer undesirable effects [153]. Especially the risk of thyroid gland dysfunction, but also the relatively high potential for allergic sensitization, has led to a restricted application of PVP-I during recent years.

The macromolecular carrier system of PVP and the release of iodine after degradation by reacting agents result in lower iodine absorption, cytotoxicity, and sensitization, and thus in better tolerability than aqueous or alcoholic iodine solutions. In aqueous solutions, only a thousandth of the total iodine is free and microbically active. The development of liposomal PVP-I compositions (PVP-I-L) on the basis of hydrogel improved the wound tolerability [30, 154].

In contrast to PVP-I, cadexomer-iodine (C-I) uses a hydrophilic, modified starch polymer to embed iodide ions. The advantages of C-I are similar to those of PVP-I; however, PVP-I and C-I show different properties regarding the reactivity of iodine and water absorption [155]. C-I did not become as widespread in German-speaking regions as PVP-I did.

In vitro and Animal Experiments

The microbicidal effect is observed for all vegetative pathogens, including mycobacteria, yeasts, and dermatophytes, enveloped and nonenveloped viruses (including rabies especially in combination with alcohols), as well as protozoa, and, with a longer exposure time (2–24 h), also bacterial spores [156]. Depending on the test model, the efficacy of PVP-I in vitro can be higher than, comparable to, or less than OCT and PHMB; 10% sheep blood does not affect the efficacy. In 10% serum albumin as well as 4.5% sheep blood + 4.5% serum albumin + 1% mucin, the exposure time doubles, similar to OCT [38, 39]. In contrast to OCT and PHMB, PVP-I has no remanent effect. Extended antiseptic effects, shown in vitro, are not due to a true remanent effect in PVP-I, in contrast to OCT or CHD, but are an artifact of the modified release kinetics of the iodine from the PVP molecule, which follows the second order of kinetics.

In vitro, PVP-I inhibits the formation and release of inflammatory mediators due to the reduced expression of bacterial exotoxins, the inhibition of excessive mediator molecule release, and the activity of human immune effector cells, as well as the inactivation of tissue-destroying enzymes [157, 158]. Through chemical reactions with the physiological H₂O₂ peroxidase systems, oxidation products with a higher efficacy than that of molecular iodine can be formed in wounds [156]. C-I ex vivo and in animal models has a strong effect against biofilm-forming S. aureus and P. aeruginosa [159]. The contrasting effects against biofilms are attributed to the different availability of active iodine in the various forms administrated [160]. In animal experiments, the healing of skin wounds was significantly delayed by 2% PVP-I [161]. For PVP-I-L, proliferation and improvement of microcirculation have been demonstrated in vitro and animal experiments [30, 162, 163]. In animal models, the application of C-I promotes epithelial cell regeneration and thus wound healing [164, 165]. In PAOD (peripheral arterial occlusive disease)-associated ulcers, C-I was tolerated without irritation [166]. In accordance with this, in histological tests, no tissue damage was observed in the treatment of chronic exudative wounds [167]. There is no evidence of neurotoxicity, mutagenicity, carcinogenici-
ty, or teratogenicity [156, 168]. In the cell culture (fibroblasts), 0.45% C-I was found to be noncytotoxic [167].

**Side Effects**

Iodophores display a high sensitization potential [169]. In adults with no known thyroid disease, and in contrast to premature infants and newborns as well as small children, irreversible damage to the thyroid gland is not to be expected after a single antisepctic application of PVP-I. However, even in patients who do not have a thyroid condition, PVP-I should not be used for more than 7 days due to a risk of thyroid dysfunction [156]. Rare extrathyroidal side effects have been described, such as iodine acne, runny nose, conjunctivitis, gastroenteritis, bronchitis, parotid swelling, and renal impairment [170]. In the case of C-I application, temporary pain may also occur [171].

**Clinical Studies**

Clinically, wound healing was generally not impaired by PVP-I. However, in some cases the control group had a better outcome [172], probably promoted by C-I [165], although PVP-I showed worse results than OCT and PHMB in terms of biocompatibility [173]. On the one hand, PVP-I has been shown to be less comfortable than medical honey and less effective in reducing the wound size than silver dressings [174], but on the other hand, it was superior to silver and C-I dressings regarding the amount of pain during medical dressing changes [175].
In a prospective randomized controlled trial (RCT), PVP-I-L was significantly more effective and tolerable than a CHD-impregnated layer on a mesh graft [30]. Overall, iodophores offer no significant advantages over PHMB, active ingredients and wound dressings containing silver, medical honey, and nonantiseptic treatments. Exploitation of the antiseptic and cytotoxic properties of iodine in the treatment of pathological granulation tissue or hypergranulation tissue is of particular interest in wound healing. This is due to the mode of action, i.e., the pathophysiological approach of preventing tissue destruction by combating the “low-grade” infection (Fig. 2a, b), unlike in conventional methods, such as silver nitrate etching or surgical resection. Within 2–3 weeks of treatment with iodine gauze, fragile, bleeding hypergranulation tissue transforms into stable, healthy, vital granulation tissue.

Caveats
Considering the broad availability of new antiseptics, the application of iodophores must be evaluated carefully [176]. If PVP-I is continuously used, thyroid function must be checked in patients with euthyroid goiter, or in patients with any known thyroid disease, during pregnancy and lactation, and before extensive use in premature and newborn infants, as well as in infants up to 6 months old. Because of its cytotoxicity, repeated use is not recommended in chronic wounds, especially on transplanted mesh grafts (this does not apply to PVP-I-L).

Contraindications
PVP-I allergy, hyperthyroid goiter, dermatitis herpetiformis Duhring, use before and after radioiodine treatments, as well as peritoneal lavage [156] contradict the use of C-I. Hashimoto’s thyroiditis, pregnancy, lactation, and an age below 12 years are additional contraindications for C-I [171].

Taurolidine
Taurolidine was introduced in 1981, and although initial results seemed promising, scientific studies still show unsatisfactory results.

In vitro and Animal Experiments
Due to the slow elimination of the formaldehyde molecule, the antiseptic efficacy of taurolidine only begins after 6–24 h in vitro [177]. Therefore, antiseptic efficacy can only be expected in long-term applications. Another mode of action is based on the antiendotoxin effect of the cross-linking of muramyl peptides in the bacterial cell wall by transferring methylol groups from the taurolidine molecule. This is intended to reduce the release of inflammatory mediators. In peritonitis, the inflammatory-induced serum levels of TNF-α and interleukin-1 decreased, and the survival rate increased after the application of taurolidine [178, 179]. Furthermore, the activity of fibroblasts, the hydroxyproline tissue levels, and the mechanical stability in anastomoses increased [180]. In a monoculture cell culture of human amniotic cells, no cytotoxicity was detected even with complete replacement of the cell culture medium by taurolidine 2% [181]. On peritoneal explants, taurolidine Ringer 0.5% was completely tolerated (with a slight increase of growth promotion). Regarding the tolerability of peritoneal explants, taurolidine 2% was comparable to 0.04% PHMB [182]. Despite the good in vitro tolerability of taurolidine, epithelization was significantly delayed in secondary wound healing in the animal model (rat) [183].

Clinical Studies
Despite the the expectations due to the mechanism of action and the proven partial reduction of the bacterial count in the peritoneum, the outcome did not verifiably improve after a prophylactic peritoneal lavage [184], nor did it improve the outcome when treating sepsis and various forms of peritonitis [185–188], compared to rinsing with physiological NaCl solution. After a first unsuccessful treatment of septic ulcers with 0.04% PHMB or 8-quinolinol, bacteria were eliminated after changing to taurolidine 2% (soaked dressings) after 2, 6, and 7 days. Although a patient showed a slower elimination of bacteria, his status continuously improved and the wound showed good epithelization after 28 days, such that the patient could be transferred to outpatient treatment [189]. Because of associated pain, taurolidine had to be combined with a local anesthetic. Due to limited data, currently taurolidine cannot be recommended for wound antisepsis.

Silver Ions
Silver-releasing compounds have been used since ancient times for wound treatment. However, silver in its elemental form has no antimicrobial effect. Antimicrobial activity develops only after the silver atoms lose an electron and become positively charged silver ions.

42 Skin Pharmacol Physiol 2018;31:28–58
DOI: 10.1159/000481545
Kramer/Dissemond/Kim/Willy/Mayer/Papke/Tuchmann/Assadian
Silver ions bind to peptide glycans of the bacterial cell membranes and thus lead to their destruction. Silver ions, which are transported into the cell, interfere with numerous cell functions by binding to proteins and interfering with energy generation, enzyme function, and cell replication. Thanks to these diverse points of attack, the development of resistances against silver ions has to date only been rarely described [190].

Clinical Studies
A great practical problem in the evaluation of wound therapeutics with silver is based on the extreme heterogeneity of the products. Thus, it is not surprising that 2 Cochrane meta-analyses [191, 192] have come to the following conclusions: silver can inhibit wound secretion and odor, and some studies showed a promotion of wound healing, but other studies showed a delay in wound healing. Currently, there are not enough studies with high-level evidence for a general recommendation of silver-containing wound dressings to improve wound healing or to treat or prevent wound infections. However, this also applies to most other antiseptic therapeutics used for wound treatment. A recent meta-analysis of clinical trials over the last 15 years shows that out of 39 clinical trials on the subject of silver in wound treatment, 31 were RCTs. In 28 of the 39 controlled studies, positive aspects were described for wounds, such as accelerated wound healing and bacterial reduction as well as positive aspects in quality of life or pain reduction. On the basis of an expert recommendation, the use of silver in the treatment of critically colonized or infected wounds, as well as in the case of a detected MDRO, was recommended for a maximum of 14 days. After this period, a critical reevaluation of the usefulness of silver-ion therapy should be performed. However, an extensive, long-term and prophylactic use was not recommended [190].

Inadvisable or Obsolete Agents

CHD has now generally been replaced by OCT, PHMB, and, in the case of acute bite wounds, PVP-I. The reasons for this are the risk of anaphylactic reactions [193], the progressive development of resistant microbes, and the increased cytotoxicity compared to OCT and PHMB. Topical silversulfadiazine has lost its significance based on recommendations to avoid the topical use of chemotherapeutics, its cytotoxicity, its risk of absorptive side effects, and the unwanted formation of hardly soluble complexes between the cream and wound proteins making wound analysis (burn depth detection) virtually impossible in burn patients. Therefore, the indication for necessary surgical treatment in patients with deep second-degree burns may be overlooked or delayed due to the adherent scab [194]. Chinolinole [195] and nitrofural [196] do not meet the formal requirements of an effective antiseptic agent, nor are there convincing clinical data proving their efficacy. Moreover, both agents bear toxic risks, and the risk-benefit analysis speaks against their use. Dyes, organic mercury compounds, pure H2O2, as well as topical antibiotics, are considered obsolete [194].

Recommended Antiseptic Agents

Table 10 shows a comparison of indications for most antiseptics (no comparative studies exist between NaOCl/HOCl, OCT and PHMB) according to the literature.

OCT: The combination 0.1% OCT/PE solution is suitable for acute, contaminated, and traumatic wounds, including MRSA-colonized wounds, due to its deep action. For chronic wounds, preparations with 0.05% OCT are preferable. The latter are available as gels or rinses combined with surface-active ethylhexyglycerin.

PHMB: The following recommendations can be made according to a literature review: level A (= strong support that merits application): therapeutic option for acute traumatic wounds, chronic ulcers and second-degree burns due to its analgesic effect; level B (= moderate support that warrants consideration of application): (cost-)effective treatment of wound infections, promotion of wound healing, and treatment of moderately exuding recalcitrant wounds [197]. Therefore, PHMB may be considered the first-choice agent for infected chronic wounds and burn wounds (gel, dressing). Furthermore, PHMB efficiently decolonizes MRSA in chronic wounds. In surgery, PHMB reduced the rate of SSI after primary debridement, placing external fixator entry ports, and poststernotomy sutures after cardiac surgery. However, due to its retrospective cohort study design and small sample size (Table 7), more evidence is needed for the latter indications. Given its spectrum of activity, PHMB is considered active against Gram-negative MDROs. However, the results of broad-spectrum tests leave some doubt as to whether PHMB is an effective agent for the treatment of VRE [39].

Hypochlorite: NaOCl or NaOCl/HOCl are first-choice agents for single or repetitive intensive, antiseptic cleans-
ing of contaminated traumatic wounds and for the repet-itive antiseptic cleansing of chronic wounds for the duration of the cleaning phase. Colonization with MRSA is effectively eradicated. OCl\(^{-}\) may even be used for antisepsis when structures of the CNS are exposed or, in the case of peritonitis, as an antiseptic agent for peritoneal lavage.

PVP-I: a recent systematic review [172] concludes that PVP-I should no longer be used in the treatment of chronic wounds. This, however, does not apply to liposomal PVP-I (PVP-I-L), as epithelialization is promoted [198]. Detailed studies investigating improved PVP-I formulations are lacking; thus, the effectiveness of PVP-I-L on healing of chronic wounds cannot definitely be assessed at this stage. There is a lack of evidence for the use of PVP-I as a cleansing solution for the prevention of SSI in acute traumatic soft tissue injuries [21]. However, in combination with alcohol, e.g., ethanol, PVP-I is still the first-choice agent for infection prevention in acute stab, cut, bite, or gunshot wounds due to its ability to penetrate deeply into the wounds [199]. Its excellent tissue penetration makes PVP-I (only on an aqueous basis!) a possible candidate for use in the heavily destroyed tissue of traumatic wounds, such as those resulting from car-crashes or explosions.

**Basic Rules of Antiseptic Treatment in Wound Management, Based on Wound Type**

- Before the application of an antiseptic agent, the following rules must be considered [200]:
  - Determine the correct diagnosis (i.e., etiology) of any chronic, nonhealing wound! The best antiseptic is ineffective if the initial cause for infection is not treated.
  - Cleansing and debridement of chronic wounds are crucial! Otherwise, antiseptics are ineffective.
  - Manage any wound according to its healing phase, especially regarding wound dressings [201]. Every dressing change should be done meticulously following basic antiseptic rules [202].

As a matter of principle, the therapeutic regimen should be reviewed after 2 weeks of unsuccessful application of an antiseptic, including further diagnostics and, for example, analyzing local blood flow in order to avoid continuing an unsuccessful regimen ad infinitum. Although rinses usually do not have a predetermined limit for the duration of their application due to their status as an MD, this practice should also be implemented when treatment with these solutions proves unsuccessful.

**Bite and Stab Injuries [199, 203]**

Acute open wounds should be thoroughly debrided and rinsed with PVP-I/alcohol. In case of contraindications, OCT/PE is a promising option. In the first 4 h, no antibiotic prophylaxis is needed and open wound treatment is continued.

In the case of virtually “closed” acute injuries (e.g., cat bites), deep surgical debridement must be carried out and the wound should be covered by a PVP-I/alcohol- or OCT/PE-soaked dressing. Alternatively, if a distal phalanx is involved, for example, the finger could be immersed in a PVP-I/alcohol or OCT/PE bath. PHMB does not exhibit a deep effect without adjuncts enhancing deep penetration. The penetration depth for hypochlorites is unknown.

For injuries or wounds older than 4 h, besides following the above rules, antibiotics should be administered orally or intravenously according to current guidelines (e.g., empirical evidence supports starting with ampicillin or amoxicillin; in most cases, a single injection will suffice).

For injuries or wounds older than 24 h, the same rules apply. However, if the wound seems clinically inflamed or infected, excision should be considered and antibiotics are usually administered for a longer period. Surface-active antiseptics should not be applied under pressure and continuous drainage should be guaranteed.

**Burns**

For possibly lethal cases, the administration of broad-spectrum antibiotics is crucial. After necrosectomy and escharotomy, the wounds and, later, freshly applied skin grafts are continuously moistened with antiseptics. Adjuvant systemic treatment consists of specific, adequate nutritional support and the substitution of factors that promote wound healing [204]. However, smaller burns can be managed and healed conservatively using antiseptic dressings [205]. Antiseptics of choice are gels on the basis of PHMB. The effectiveness of devices and dressings containing silver ions remains unclear [191, 192, 194, 206, 207, 272].

**Antiseptic Irrigation/Rinsing**

It has been shown that a single irrigation/rinse with an antiseptic agent reduces the SSI rate after surgical management of acute, contaminated wounds [21]. The same holds true for intraoperative irrigation/rinsing before surgical wound closure [208].
Decolonization of MRSA-Colonized Wounds

The main indication for decolonization is to prevent the spread of nosocomial infections. Decolonization of MRSA in the nasal vestibule is usually successful after 7 days [209]. Burn wounds are decolonized after 5 days [210], whereas chronic wounds need to be treated with mupirocin for 14 days [211, 212].

Treatment of Locally Infected or Critically Colonized Wounds

For these types of wounds, routine treatment with an antiseptic agent is required (examples are given in Tables 6–9).

Future Perspectives

NPWT with Instillation of Antiseptic Agents

NPWT exerts no direct antimicrobial effect. Therefore, instillation of an antiseptic agent in combination with NPWT, called NPWTi, is being increasingly promoted as a promising combination in wounds with a heavy bioburden [213–218].

NPWT may be considered a special form of semiocclusive “moist” wound dressing with virtually unlimited drainage capacity. Through direct contact and interaction of the foam with the wound, the granulation process is promoted [216] and tissue perfusion improved [219]. In an animal model, where excision wounds on the back of pigs were infected with P. aeruginosa, instillation of physiological NaCl combined with NPWT (NPWTi) was clearly more effective in reducing the bioburden than NPWT alone; instillation with PHMB significantly enhanced this effect [220]. Positive results of smaller studies using PHMB, mostly without long-term follow-up [221], have recently only been partially confirmed by larger, systematic studies (Table 10). Therefore, further RCTs are needed to clarify the role of PHMB in NPWTi. Further experiments in infected pig wounds showed a significant reduction of bioburden after 48 h using a combination of NPWT and a dressing containing silver ions, as well as with cyclic instillation of OCT (for 3 min every 4 h) and NPWTi compared to NPWT alone [222]. In an exemplary case of a patient with a high-risk of skin graft failure due to comorbidities, the application of NPWTi with OCT led to uneventful healing. A second patient developed skin graft necrosis after the use of PVP-I; regrafting and a change to NPWTi with OCT was followed by uncomplicated healing [223]. In both studies, a solution with 0.05% OCT without the addition of PE was used. Grade-4 gluteal pressure ulcers 4 (n = 3) treated by NPWTi with OCT healed completely within 4 weeks [224]. Representative studies (e.g., RCTs, larger prospective cohort studies) using NPWTi in combination with OCT are still lacking. The single study of NPWTi with NaOCl has merely indicative character (Table 11). Due to aseptic necrosis after the application of OCT into tissue, Willy et al. [225] recommend a limited use of NPWT with OCT in case of deeper injuries.

Acetic Acid

Generally speaking, an acidic wound environment supports control of infection, toxicity of bacterial metabolites, protease activity inhibition, release of oxygen, and epithelialization as well as angiogenesis [226].

In vitro and Animal Study Results

AA is, just like NaOCl/HOCl, a physiologically active substance. It was already noticed in 1916 that colonization with P. aeruginosa was only rarely observed in an acidic wound environment [227]. When comparing different acids, AA showed a superior effect [227, 228]; at pH 3, the antimicrobial effect was 10–100 times stronger compared to other acids. It is assumed that undissociated AA is able to penetrate the cell better due to improved lipid solubility. The MIC (agar dilution test, 72 h) was observed to be 9% for S. aureus, 8–10% for MRSA, 4% for E. coli, 3% for Salmonella typhi, and 2% for P. aeruginosa [229, 230]. In the dilution test (18 h) MIC varied between 0.16 and 0.31%. Biofilms were eliminated by 0.31% AA in 3 h [231]. The following reduction rates were obtained in suspension tests with concentrations that were nontoxic for fibroblasts after 15 min: 0.005% NaOCl > 8 log versus S. aureus, P. aeruginosa, E. coli, Enterococcus spp., and Bacteroides fragilis. 0.0025% AA was only effective against S. aureus with <1 log₁₀ and P. aeruginosa with 3 log₁₀, 0.001% PVP-I was effective only against S. aureus with 3 log₁₀ and P. aeruginosa with <1 log₁₀, while 0.003% H₂O₂ was ineffective against all test organisms [232]. In the quantitative suspension test, 1% AA eliminated Proteus vulgaris, P. aeruginosa, Acinetobacter baumannii, and β-hemolytic streptococci within 5 min, and S. aureus and S. epidermidis within 10 min. 0.04% PHMB, OCT/PE, and PVP-I 11% also only needed 5 min to accomplish this, but 10 min were necessary against P. vulgaris [233]. In cell culture with fibroblasts, 1% PVP-I (IC₁₀₀), 3% H₂O₂ (IC₁₀₀), 0.5% NaOCl (IC₁₀₀), and 0.25% AA (IC₂₅) proved to be cytotoxic [47]. In an animal model with aseptic wounds down to the fascia, epithelialization was only delayed significantly up to the 8th day with the tested concentrations, and H₂O₂ proved completely ineffec-
Table 9. Summary of clinical study findings for PVP-I or PVP-I-L and C-I

<table>
<thead>
<tr>
<th>Type of wound</th>
<th>Comparison</th>
<th>Result</th>
<th>Study design</th>
<th>Sample size, n</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>VLU</td>
<td>C-I vs. standard treatment</td>
<td>Improved wound healing and lower costs with C-I</td>
<td>Review</td>
<td>4 RCTs</td>
<td>2016 [312]</td>
</tr>
<tr>
<td>Pressure ulcers (infected and noninfected)</td>
<td>PVP-I and C-I vs. nonantimicrobial treatment, lysozyme ointment, crystal violet, PHMB, silver sulfadiazine</td>
<td>Little evidence for improved wound healing in nonantimicrobial wound treatment interventions and noninfected wounds as compared to PVP-I</td>
<td>Cochrane review</td>
<td>12 RCTs</td>
<td>2016 [313]</td>
</tr>
<tr>
<td>VLU</td>
<td>PVP-I vs. hydrocolloid dressings</td>
<td>No observable differences</td>
<td>Cochrane review</td>
<td>6 RCTs</td>
<td>2014 [314]</td>
</tr>
<tr>
<td>Infected wounds</td>
<td>PVP-I vs. silver foam dressing</td>
<td>Significantly faster wound size reduction with silver</td>
<td>RCT</td>
<td>35/35</td>
<td>2014 [315]</td>
</tr>
<tr>
<td>Chronic wounds</td>
<td>PVP-I vs. medical honey</td>
<td>Improved results with medical honey in terms of wound size reduction, comfort, and pain during dressing change</td>
<td>RCT</td>
<td>20/22</td>
<td>2014 [174]</td>
</tr>
<tr>
<td>Chronic wounds</td>
<td>PVP-I vs. C-I vs. silver dressing</td>
<td>PVP-I: improved comfort and less pain during dressing change, lowest costs</td>
<td>Cohort study</td>
<td>20</td>
<td>2013 [175]</td>
</tr>
<tr>
<td>Chronic wounds,burns, pressure ulcer</td>
<td>29 RCTs comparing efficacy of PVP-I and C-I with hydrocolloids, silver, zinc, dextranomer, and NaCl solution</td>
<td>In some RCTs advantage of PVP-I over nonantiseptics and other antiseptics, particularly for burns; otherwise no benefit of one method against the other</td>
<td>Review</td>
<td>29 RCTs</td>
<td>2010 [172]</td>
</tr>
</tbody>
</table>

Table 10. Summary of clinical findings for wound antiseptics

<table>
<thead>
<tr>
<th>Criteria</th>
<th>NaOCl/HOCl</th>
<th>OCT</th>
<th>PHMB</th>
<th>PVP-I</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antimicrobial efficacy</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Improvement of wound healing</td>
<td>Yes</td>
<td>No inhibition</td>
<td>Yes</td>
<td>Partly inhibition</td>
</tr>
<tr>
<td>Peritoneal lavage in septic peritonitis</td>
<td>Possible</td>
<td>Contraindicated</td>
<td>Contraindicated</td>
<td>Contraindicated</td>
</tr>
<tr>
<td>Applicability of CNS tissue</td>
<td>Possible</td>
<td>Contraindicated</td>
<td>Contraindicated</td>
<td>Toxic [316]</td>
</tr>
<tr>
<td>Applicability on cartilage</td>
<td>Possible</td>
<td>Contraindicated</td>
<td>Only at &lt;0.005%</td>
<td>Yes</td>
</tr>
<tr>
<td>Superior to</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ag⁺ PVP-I CHD</td>
<td>Tendentially better</td>
<td>Significantly better</td>
<td>Tendentially better</td>
<td>Tendentially better</td>
</tr>
<tr>
<td>CHD</td>
<td>Significantly better</td>
<td>Tendentially better</td>
<td>Significantly better</td>
<td>–</td>
</tr>
<tr>
<td>Prevention of SSI</td>
<td>Possible</td>
<td>No studies</td>
<td>Effective</td>
<td>Tendentially better</td>
</tr>
</tbody>
</table>
The tear resistance of wounds was not impaired. S. aureus was eliminated by noncytotoxic concentrations of PVP-I (0.001%) and NaOCl (0.005%). For H₂O₂ and AA, however, the noncytotoxic concentrations proved ineffective [47]. A 0.15% AA solution stimulated wound healing [161]. For experimental wounds on rats and human split-skin removal sites, wound healing was generally accelerated with 0.25% AA, 11% PVP-I, and 3% H₂O₂, but after detachment of the scab, H₂O₂ caused blisters and ulcerations in contrast to AA and PVP-I [234].

Adverse Effects
On wounds, concentrations >2% caused pain [230] and >5% caused a burning sensation [235].

Clinical Studies
The concentrations effective for eliminating P. aeruginosa on small ulcerations and burns varied between 1 and 5%, and eradication occurred after 2–16 days [230, 235–239]. In burn patients, P. aeruginosa was eliminated after 2–17 days following a daily bath in 0.5% AA for 22–45 min [235]. After cleaning the wound with sterile NaCl solution, a compress drenched in 3% AA was changed daily and fixated via dressing. After 2–12 days, P. aerugi-

Table 11. Summary of clinical study findings for NPWTi

<table>
<thead>
<tr>
<th>Type of wound</th>
<th>Comparison</th>
<th>Result</th>
<th>Study design</th>
<th>Sample size, Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infected wounds</td>
<td>NPWTi PHMB/PVP-I vs. NPWTi with NaCl solution</td>
<td>No difference in the number of surgical procedures, length of stay, wound healing rate; with NaCl: significant reduction in time to final surgical treatment</td>
<td>RCT</td>
<td>100/83 2015 [317]</td>
</tr>
<tr>
<td>Chronic wounds</td>
<td>NPWT vs. NPWTi PHMB + PVP-I</td>
<td>PHMB: significantly fewer dressing changes, shorter hospitalization, shorter surgical procedure times, faster wound closure, faster bacterial elimination</td>
<td>Retrospective case-control study</td>
<td>74/68 2014 [221]</td>
</tr>
<tr>
<td>Chronic wounds</td>
<td>PHMB-soaked gauze vs. NPWTi with PHMB-impregnated gauze</td>
<td>NPWTi: significantly better wound healing, shorter treatment time, elimination of bioburden</td>
<td>RCT</td>
<td>25/25 2013 [318]</td>
</tr>
<tr>
<td>Chronic wounds</td>
<td>NPWT vs. NPWTi with NaOCl 0.125%</td>
<td>Significant reduction of bacterial load per gram of tissue compared to NPWT alone</td>
<td>Prospective randomized sequential study</td>
<td>8/8 2012 [319]</td>
</tr>
<tr>
<td>Osteomyelitis</td>
<td>NPWTi with PHMB vs. historic control</td>
<td>PHMB: significantly faster reduction of infection, shorter hospitalization, fewer surgical interventions</td>
<td>Retrospective case-control study</td>
<td>30/94 2009 [320]</td>
</tr>
</tbody>
</table>

Contraindications
No contraindications are known.

Cold Atmospheric Plasma
Cold atmospheric plasma (CAP) is included in this analysis because it mainly consists of reactive-oxygen species (ROS) and nitrogen species (NO), and thus has highly antiseptic properties. It significantly surpasses PVP-I and PHMB in efficacy [241]. Against biofilms, it performs almost as well as PHMB and CHD [242]. On the skin, the efficacy is only slightly lower than that of OCT [243]. The plasma’s idiosyncrasy is that biochemically active compounds are created instrumentally and display other qualities in addition to the antimicrobial effect. As with the introduction of portable laser technology and associated innovations, the development of mobile devices [244, 253] allows multiple local plasma applications. At
the moment, these are focused around the therapy of chronic wounds [245–249], tumors [250], and eliminating biofilm on implants [251–253].

The biochemically active compounds (electrons, ions, excited atoms and molecules such as ROS and NO, atoms or molecules with unpaired electrons, photons or electromagnetic fields) are created during plasma generation through interaction with molecules from the surrounding air and/or medium and body fluids or tissue.

The hypothesis [254, 255] for the analysis of plasma used in wound healing is founded on the following assumptions:
- Every healing process requires energy
- The center of chronic wounds is hypoxic and hypothermic, and an energy deficit will inhibit wound healing
- A higher tissue temperature (>38°C), elevated oxygen partial pressure (to provide aerobic energy), and increased blood circulation (for the transport of energy-rich substrates and metabolites) support wound healing
- Damaged cells in the wound area inhibit wound healing
- Critical colonization/biofilm formation or infection will block wound healing
- Endotoxin absorption or binding facilitate wound healing
- The existence of induced electrical flow and ion distribution based on electrical signals are important for cell migration and distribution at the edge of the wound

### In vitro and Animal Experiment Findings

The microbicidal effect of CAP was observed in vitro [256–261] on skin and chronic wounds, and exceeds the effectiveness of CHD, PVP-I, and PHMB. In a 3D epidermis model, CAP displayed dose- and time-dependent compatibility [256]; *P. aeruginosa* was inactivated without destroying the structure of the epidermis. Cell proliferation is supported in cell culture [247]. For degree-IIa superficial dermal wounds and degree-III wounds with complete loss of skin on pigs, the wound healing duration did not differ from the control, and no increase in inflammation reactions or cell atypia was found. An increased IL-6 and IL-8 release was induced for keratinocytes and mononuclear cells. The support of circulation and angiogenesis was also observed [262]. On the chorioallantoic membrane, a heightened leukocyte-endothelium interaction with an increased fraction of rolling leukocytes and leukocytes solidly attached to the vascular endothelium (as a precursor to diapedesis into the surrounding tissue) was documented [247, 263]. This may signal an increase in inflammatory and immunological reaction due to the stimulus caused by CAP. No mutagenic potency was documented for the plasma source used in these experiments [264].

### Clinical Results

The healing of chronic wounds for small animals (treatment duration 4–5 s/cm² of wound surface, twice a week) supports the hypothesis that the healing process starts with an intermediate acute inflammation. Because

### Table 12. Summary of clinical study findings for AA

<table>
<thead>
<tr>
<th>Type of wound</th>
<th>Comparison</th>
<th>Result</th>
<th>Study design</th>
<th>Sample size, n</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic wounds</td>
<td>1% AA vs. NaCl</td>
<td>AA: <em>P. aeruginosa</em> reduced significantly faster (day 7)</td>
<td>RCT</td>
<td>16/16</td>
<td>2016 [230]</td>
</tr>
<tr>
<td>VLU</td>
<td>0.25% AA vs. 0.25% chloramine</td>
<td>AA: 15-min wet-to-moist gauze application yielded a significant reduction of total colony count and <em>S. aureus, P. aeruginosa, Proteus spp., S. epidermidis, and S. haemolyticus</em> group G with both test compounds was not reduced significantly</td>
<td>Quasi-experimental intervention study</td>
<td>45</td>
<td>1995 [321]</td>
</tr>
<tr>
<td>Burns or superficial wounds</td>
<td>5% AA vs. CHD or hypochlorite</td>
<td>AA: elimination of <em>P. aeruginosa</em> within 2–7 days in 8/10 patients and 1/10 after 4 days in the control group</td>
<td>RCT</td>
<td>10/0</td>
<td>1968 [238]</td>
</tr>
</tbody>
</table>

Downloaded by: 165.225.72.124 - 12/21/2017 10:11:22 AM
CAP exhibits no remanent effect, OCT or PHMB was applied after each plasma treatment. The wound dressing was renewed daily and the wound was cleaned with the initially used antiseptic [265]. Regarding chronic ulcers in humans, however, no corresponding results were achieved, probably since CAP was not used in conjunction with remanently effective antiseptics [266]. There was no evidence of adverse reactions on human skin or chronic wounds. The penetration depth never exceeded 60 μm [247].

Caveats
Because of oxidative stress, the resulting formation of ROS and NO, and an increase in the inflammation cascade in burn wounds [267], application of CAP on burns should not be started before its safety has been confirmed in animal-based experimental studies.

Contraindications
No contraindications are known.

Conclusion and Practical Recommendations
Wound antiseptics are indicated for the treatment of critically colonized and infected chronic wounds, to prevent the development of infection in acute wounds with increased risk of infection, such as bites, stabs/punctures, or burns, for decolonization of wounds colonized with MDROs, and for the prevention of SSI. In case of a longer surgery duration (about ≥1 h), a single rinsing of the surgical area appears to be reasonable [225], since more than 50% of all surgical gloves are contaminated during this time [268].

Due to the paucity of clinical studies, the selection of wound antiseptics is based on both preclinical and clinical studies of nonuniform research quality and design. After assessing characteristics and the available research, it can be summarized that for critically colonized and infected chronic wounds as well as for burns, PHMB is the antiseptic of choice. For bites, stabs/punctures, and gunshot wounds, PVP-I is the first agent of choice, while PHMB and hypochlorite are superior to PVP-I for the treatment of contaminated acute and chronic wounds. For the decolonization of MDRO-colonized or infected wounds, the combination of OCT/PE is preferred. For peritoneal lavage or rinsing of other cavities with a lack of drainage potential as well as when the risk of CNS exposure exists, hypochlorite is the antiseptic of choice (Table 13).

Addendum
This consensus document was reviewed and formally approved by the respective boards of the following scientific societies: Antiseptics Working Group of the International Society of Chemotherapy for Infection and Cancer (ISC), German Society for Hospital Hygiene (Deutsche Gesellschaft für Krankenhaushygiene, DGKH), the Chronic Wound Initiative (Initiative Chronische Wunden e.V., ICW), Austrian Society for Infection Control (Österreichische Gesellschaft für Krankenhaushygiene, ÖGKH), Organization of all German-speaking Societies and Groups in Wound Management (Dachorganisation deutschsprachiger Vereine und Gruppen im Bereich Wundmanagement, Wund-D.A.CH).

<table>
<thead>
<tr>
<th>Table 13. Orientating recommendation for the indication-based selection of wound antiseptics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indication</strong></td>
</tr>
<tr>
<td>Critically colonized wounds, wounds at risk of infection</td>
</tr>
<tr>
<td>Burns</td>
</tr>
<tr>
<td>Bite, stab, and gunshot wounds</td>
</tr>
<tr>
<td>MDRO-colonized or infected wounds</td>
</tr>
<tr>
<td>Prevention of SSI</td>
</tr>
<tr>
<td>Decontamination of acute and chronic wounds</td>
</tr>
<tr>
<td>Peritoneal lavage</td>
</tr>
<tr>
<td>Risk of CNS tissue exposure</td>
</tr>
<tr>
<td>Wounds with lack of drainage</td>
</tr>
</tbody>
</table>
Disclosure Statement

Axel Kramer discloses that in the past he has received research support, lecture fees, and travel-cost reimbursements from the following companies: Antiseptika chem.pharm. GmbH, B. Braun Melsungen AG, Bode/Paul Hartmann AG, Lohmann and Rauscher, Maquet GmbH, Schülke and Mayr GmbH, SERAG – WIESSNER GmbH and Co. KG, Oculus, Ethicon, and 3M Healthcare. However, the present publication is not connected with financial interests.

Joachim Dissemond discloses that in the past he has received research support, lecture fees, and travel-cost reimbursements from the following companies: Acelity, B. Braun, Coloplast, Convatec, Draco, Engelhard, Flen Pharma, Lohmann & Rauscher, Mölnlycke, Seriag-Wiesner, and Urgo.

Ojan Assadian was a member of the Hutchinson Sante’s medical advisory board and Mölnlycke Medical Advisory Board. He declares having previously received travel and accommodation expenses, together with honoraria for teaching and participation in advisory/consultation groups from: Altreaal Europe Ltd., Antiseptica chem. GmbH, B. Braun Melsungen AG, Carefusion Ltd., Coloplast AG, Ethicon Ltd., KCI Austria GmbH, Lohmann and Rauscher GmbH and Co. KG, Maquet GmbH, Mentor Deutschland GmbH, Mundipharma GmbH, Nawa Heilmittel GmbH, Quantum Management and Service GmbH, Schülke and Mayr GmbH, Smith and Nephew Ltd, and 3M Deutschland GmbH. Prof. Assadian declares that he has no stocks or other financial interests with any company or their products.

All other authors have no conflicts of interest to declare.

The present publication is not connected with financial interests. Where specific products are mentioned, the authors expressed personal opinion, based on scientific evidence and published data, with no company involvement.

References


229 Juma IM, Yass HS, Al-Jaberi FH: Comparison between the effect of acetic acid and salicylic acid in different concentrations on Pseudomonas aeruginosa isolated from burn wound infection. Al Taqani 2007;20:73–78.


Consensus on Wound Antisepsis: Update 2018


